RPHM Reneo Pharmaceuticals
- 1.860
- +0.030+1.64%
- 1.860
- 0.0000.00%
Reneo Pharmaceuticals News
Reneo Pharmaceuticals | 10-Q: Quarterly report
Press Release: Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically f
Reneo Pharmaceuticals 1Q Loss/Shr 25c >RPHM
Reneo Pharmaceuticals 1Q Loss/Shr 25c >RPHM
Reneo Pharmaceuticals 1Q Loss $8.43M >RPHM
Reneo Pharmaceuticals 1Q Loss $8.43M >RPHM
Sell Rating on Reneo Pharmaceuticals Amid Strategic Uncertainty and Reduced Price Target
Reneo Pharmaceuticals GAAP EPS of -$2.52
Reneo Pharmaceuticals: Q4 Earnings Insights
Reneo Pharmaceuticals (NASDAQ:RPHM) reported its Q4 earnings results on Thursday, March 28, 2024 at 07:35 AM.Here's what investors need to know about the announcement.EarningsReneo Pharmaceuticals mis
Reneo Pharmaceuticals Q4 GAAP EPS $(0.70) Misses $(0.62) Estimate; Cash, Cash Equivalents, And Short-term Investments Of $103M
Reneo Pharmaceuticals (NASDAQ:RPHM) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate of $(0.62) by 12.9 percent. This is a 25 percent decrease over losses of
Press Release: Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update
Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a
Reneo Pharmaceuticals 4Q Loss/Shr 70c >RPHM
Reneo Pharmaceuticals 4Q Loss/Shr 70c >RPHM
Reneo Pharmaceuticals Announces Workforce Reduction Costs
Reneo Pharmaceuticals to Cut 20% of Workforce in Second Round of Layoffs
By Ben Glickman Reneo Pharmaceuticals plans to cut more jobs, about 20% of its workforce, months after laying off the majority of its staff. The Irvine, Calif.-based company announced a 70% headcoun
Reneo Pharmaceuticals Inc Says On Dec 26, Concentra, An Affiliate Of Tang Capital Partners, Sent Acquisition Proposal To The Co; On Behalf Of Concentra Biosciences, Submit Non-Binding Proposal To Acquire 100% Of Equity Of Reneo For $1.80 Per Share
Concentra Biosciences, LLC4747 Executive Drive, Suite 210 | San Diego, CA 92121December 26, 2023Board of DirectorsReneo Pharmaceuticals, Inc.c/o Gregory J. Flesher, President and Chief Executive Offic
Analysts Offer Insights on Healthcare Companies: Rain Therapeutics (RAIN), Reneo Pharmaceuticals (RPHM) and Bicycle Therapeutics (BCYC)
Express News | Reneo Pharmaceuticals Inc. (RPHM) liquidates Novo Nordisk Holdings.
Ladenburg Thalmann Downgrades Reneo Pharmaceuticals to Neutral From Buy
Reneo Pharmaceuticals (RPHM) has an average rating of hold and price targets ranging from $1 to $33.81, according to analysts polled by Capital IQ. Price: 1.36, Change: +0.02, Percent Change: +1.49
Reneo Pharmaceuticals Price Target Cut to $1.50/Share From $30.00 by HC Wainwright & Co.
Reneo Pharmaceuticals Price Target Cut to $1.50/Share From $30.00 by HC Wainwright & Co.
Reneo Pharmaceuticals Cut to Hold From Buy by Jefferies
Reneo Pharmaceuticals Cut to Hold From Buy by Jefferies
Leerink Partners Downgrades Reneo Pharmaceuticals to Market Perform, Announces $1 Price Target
Leerink Partners analyst Joseph Schwartz downgrades Reneo Pharmaceuticals (NASDAQ:RPHM) from Outperform to Market Perform and announces $1 price target.
Reneo Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 12/15/2023 -27.01% Leerink Partners → $1 Downgrades Outperform → Market Perform 11/15/2023 — William Blair
Analysis
Price Target
No Data
